Journal of Medicinal Chemistry · 2015 · 28 citations · 16 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryLead OptimizationMolecular PharmacologyHit-to-lead OptimizationLead Compound DesignPotency OptimizationSelectivity OptimizationSolubility OptimizationAcute Myeloid Leukemia TherapyAqueous Solubility ImprovementAqueous Solubility OptimizationKinase Inhibitor Library DesignSelectivitySolubilityTargeted Inhibitor DesignTargeted Kinase Inhibition
The challenge for glycogen synthase kinase-3 (GSK-3) inhibitor design lies in achieving high selectivity for one isoform over the other. The therapy of certain diseases, such as acute myeloid leukemia (AML), may require α-isoform specific targeting. The scorpion shaped GSK-3 inhibitors developed by our group achieved the highest GSK-3α selectivity reported so far but suffered from insufficient aqueous solubility. This work presents the solubility-driven optimization of our isoform-selective inhibitors using a scorpion shaped lead. Among 15 novel compounds, compound 27 showed high activity against GSK-3α/β with the highest GSK-3α selectivity reported to date. Compound 27 was profiled for bioavailability and toxicity in a zebrafish embryo phenotype assay. Selective GSK-3α targeting in AML cell lines was achieved with compound 27, resulting in a strong differentiation phenotype and colony formation impairment, confirming the potential of GSK-3α inhibition in AML therapy.
16
Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation
Klaus P. Hoeflich, Juan Luo, Elizabeth A. Rubie et al. · Nature · 2000 · 1.4K citations
GSK-3-Selective Inhibitors Derived from Tyrian Purple Indirubins
Laurent Meijer, Alexios-Leandros Skaltsounis, Prokopios Magiatis et al. · Chemistry & Biology · 2003 · 815 citations · Full text
Crystal Structure of Glycogen Synthase Kinase 3β
Rana Dajani, Elizabeth Fraser, S. Mark Roe et al. · Cell · 2001 · 669 citations · Full text